Orphinic Scientific S.A. was funded in 2019 as the first Polish biotech portfolio platform creating innovative solutions for orphan diseases and other indications with significant unmet medical needs in the clinical trial phase. Orphinic core scientific team consist of experts with over 20 years experience in clinical development processes and their commercialization. The company’s competencies in clinical stage development are further enforced through a collaboration with a large clinical CRO operating in the CEE region. This facilitates access to diverse patient populations and rapid enrollment to clinical trials supporting our projects and significantly shortens the duration of individual phases. Orphinic currently has 11 projects in the pipeline that range from a preclinical phase to market approval stages in three healthcare segments: therapeutics, medtech and e-health. ⏱ We shorten time to the market due to specialized healthcare centers in CEE and an affiliated CRO. 🩺 Our team has an exceptional track record in sourcing and exiting high-quality projects. 🧬 Our portfolio represents clinic-ready assets, with first projects ready to exit in 2023, and a preclinical pipeline for long-term value creation. 💊 We invest in projects with low correlation. Average project risk of c.50% with average returns of c.10x our investment. 📈 Our plan is to IPO at Warsaw Stock Exchange by the end of 2022.